MENU
+Compare
CLSD
Stock ticker: NASDAQ
AS OF
Apr 24, 04:59 PM (EDT)
Price
$0.85
Change
+$0.05 (+6.25%)
Capitalization
61.82M

CLSD Clearside Biomedical Forecast, Technical & Fundamental Analysis

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company... Show more

CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CLSD with price predictions
Apr 23, 2025

Aroon Indicator for CLSD shows an upward move is likely

CLSD's Aroon Indicator triggered a bullish signal on April 04, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 116 similar instances where the Aroon Indicator showed a similar pattern. In of the 116 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLSD's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where CLSD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLSD advanced for three days, in of 203 cases, the price rose further within the following month. The odds of a continued upward trend are .

CLSD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CLSD as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CLSD turned negative on April 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

CLSD moved below its 50-day moving average on March 28, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CLSD crossed bearishly below the 50-day moving average on April 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLSD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLSD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (35.461) is also within normal values, averaging (252.992).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLSD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CLSD is expected to report earnings to fall 15.00% to -8 cents per share on May 08

Clearside Biomedical CLSD Stock Earnings Reports
Q1'25
Est.
$-0.09
Q4'24
Est.
$-0.10
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.03
Q1'24
Missed
by $0.03
The last earnings report on March 27 showed earnings per share of -10 cents, meeting the estimate of -10 cents. With 64.49K shares outstanding, the current market capitalization sits at 61.82M.
A.I. Advisor
published General Information

General Information

a developer of drug therapies to treat chronic, blinding diseases of the eye

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
900 North Point Parkway
Phone
+1 678 270-3631
Employees
30
Web
https://www.clearsidebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRDO40.423.40
+9.18%
Credo Technology Group Holding Ltd
SYK357.118.99
+2.58%
Stryker Corp
CTMX0.73N/A
-0.65%
CytomX Therapeutics
RES4.93-0.07
-1.40%
RPC
NATR11.34-0.36
-3.08%
Nature's Sunshine Products

CLSD and Stocks

Correlation & Price change

A.I.dvisor tells us that CLSD and INBX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLSD and INBX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSD
1D Price
Change %
CLSD100%
-0.30%
INBX - CLSD
28%
Poorly correlated
+2.44%
IKNA - CLSD
27%
Poorly correlated
+1.68%
VCYT - CLSD
27%
Poorly correlated
+1.08%
INAB - CLSD
26%
Poorly correlated
+5.39%
NXTC - CLSD
25%
Poorly correlated
+4.89%
More